More than 60 abstracts will be presented from the ViiV portfolio, including updates from the phase 1 crossover study, the first comparing the acceptability and tolerability of long acting cabotegravir ...
Experts discuss the implications of Most Favored Nation pricing on U.S. drug costs, innovation and patient access in the ...
Libtayo gained FDA approval as the first immunotherapy for high-risk cutaneous squamous cell carcinoma, promising improved ...
Vascular endothelial growth factor (VEGF) inhibitor, Eydenzelt (aflibercept-boav), is now approved to treat retinal disease ...
A recent study finds that despite biosimilar use rising to 60% to 86% for three cancer drugs, predicted savings don’t match ...
An expert discusses how insurance coverage barriers for Janus kinase (JAK) inhibitors in vitiligo treatment can be overcome ...
Emergency Medicaid spending represented only 0.4% of total Medicaid expenditures in 2022, rising to 0.9% in states with higher populations of undocumented immigrants.
Back surgeries to address age-related pain in older adults aren’t just risky, they're expensive too, according to a recent study from the Lown Institute.
Providing support and care for adults with schizophrenia can mean a significant personal and financial burden for family ...
The PIVOT-006 trial is part of a larger national effort to evaluate cretostimogene’s safety and effectiveness in bladder ...
Although neuroendocrine tumors of the digestive system have been studied, far less is known about those that develop in the ...
Jascayd targets the enzyme PDE4B, which plays a role in the inflammatory process. The new therapy is able to affect both ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback